年轻乳腺癌患者抗癌治疗前后生育力保存技术的安全性:系统评价与荟萃分析
该系统评价与荟萃分析纳入15项研究共4643例年轻乳腺癌患者,比较接受或未接受控制性卵巢刺激(COS)或辅助生殖技术(ART)者的生存结局。结果显示,诊断时行COS者复发风险(RR 0.58)和死亡风险(RR 0.54)降低,无事件生存(EFS)无显著差异(HR 0.76);抗癌治疗后行ART者复发风险(RR 0.34)有改善趋势。
要点
- 诊断时行COS与复发风险降低相关(RR 0.58,95%CI 0.46-0.73)。
- COS对EFS无显著影响(HR 0.76,95%CI 0.55-1.06)。
- 抗癌治疗后行ART者复发风险有改善趋势(RR 0.34,95%CI 0.17-0.70)。
核心结论
- 年轻乳腺癌患者诊断时行COS或治疗完成后行ART似乎不伴有不利的预后影响。
研究设计与样本
- 系统评价与荟萃分析,由三名盲法研究者检索Medline、Web of Science、Embase和Cochrane图书馆,无语言或日期限制,截至2021年6月30日,最终纳入15项病例对照或队列研究(n=4643)。
主要发现
- 与诊断时未行生育力保存者(n=2386)相比,行COS者(n=1594)复发风险降低(RR 0.58,95%CI 0.46-0.73),死亡风险降低(RR 0.54,95%CI 0.38-0.76)。
- COS对EFS无显著影响(HR 0.76,95%CI 0.55-1.06)。
- 激素受体阳性疾病行COS者EFS有改善趋势(HR 0.36,95%CI 0.20-0.65)。
- 新辅助化疗前行COS者复发风险降低(RR 0.22,95%CI 0.06-0.80)。
- 与抗癌治疗完成后未行ART者(n=540)相比,行ART者(n=123)复发风险有改善趋势(RR 0.34,95%CI 0.17-0.70),EFS有改善趋势(HR 0.43,95%CI 0.17-1.11)。
临床怎么用
- 作者认为,诊断时行COS或治疗完成后行ART似乎不伴有不利的预后影响,包括激素受体阳性疾病和接受新辅助化疗的患者。
局限性
- 本荟萃分析基于摘要数据,大多数纳入研究为回顾性队列研究。
- 并非所有研究的研究人群与对照组之间有匹配标准,且这些标准在研究间常不同。
- 复发率报告为点事件,无法确定复发发生时间,部分纳入研究随访短于5年,是否足以捕获晚期复发尚不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is it safe to perform controlled ovarian stimulation (COS) for fertility preservation before starting anticancer therapies or ART after treatments in young breast cancer patients? SUMMARY ANSWER: Performing COS before, or ART following anticancer treatment in young women with breast cancer does not seem to be associated with detrimental prognostic effect in terms of breast cancer recurrence, mortality or event-free survival (EFS). WHAT IS KNOWN ALREADY: COS for oocyte/embryo cryopreservation before starting chemotherapy is standard of care for young women with breast cancer wishing to preserve fertility. However, some oncologists remain concerned on the safety of COS, particularly in patients with hormone-sensitive tumors, even when associated with aromatase inhibitors. Moreover, limited evidence exists on the safety of ART in breast cancer survivors for achieving pregnancy after the completion of anticancer treatments. STUDY DESIGN, SIZE, DURATION: The present systematic review and meta-analysis was carried out by three blinded investigators using the keywords 'breast cancer' and 'fertility preservation'; keywords were combined with Boolean operators. Eligible studies were identified by a systematic literature search of Medline, Web of Science, Embase and Cochrane library with no language or date restriction up to 30 June 2021. PARTICIPANTS/MATERIALS, SETTING, METHODS: To be included in this meta-analysis, eligible studies had to be case-control or cohort studies comparing survival outcomes of women who underwent COS or ART before or after breast cancer treatments compared to breast cancer patients not exposed to these strategies. Survival outcomes of interest were cancer recurrence rate, relapse rate, overall survival and number of deaths. Adjusted relative risk (RR) and hazard ratio (HR) with 95% CI were extracted. When the number of events for each group were available but the above measures were not reported, HRs were estimated using the Watkins and Bennett method. We excluded case reports or case series with <10 patients and studies without a control group of breast cancer patients who did not pursue COS or ART. Quality of data and risk of bias were assessed using the Newcastle-Ottawa Assessment Scale. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 1835 records were retrieved. After excluding ineligible publications, 15 studies were finally included in the present meta-analysis (n = 4643). Among them, 11 reported the outcomes of breast cancer patients who underwent COS for fertility preservation before starting chemotherapy, and 4 the safety of ART following anticancer treatment completion. Compared to women who did not receive fertility preservation at diagnosis (n = 2386), those who underwent COS (n = 1594) had reduced risk of recurrence (RR 0.58, 95% CI 0.46-0.73) and mortality (RR 0.54, 95% CI 0.38-0.76). No detrimental effect of COS on EFS was observed (HR 0.76, 95% CI 0.55-1.06). A similar trend of better outcomes in terms of EFS was observed in women with hormone-receptor-positive disease who underwent COS (HR 0.36, 95% CI 0.20-0.65). A reduced risk of recurrence was also observed in patients undergoing COS before neoadjuvant chemotherapy (RR 0.22, 95% CI 0.06-0.80). Compared to women not exposed to ART following completion of anticancer treatments (n = 540), those exposed to ART (n = 123) showed a tendency for better outcomes in terms of recurrence ratio (RR 0.34, 95% CI 0.17-0.70) and EFS (HR 0.43, 95% CI 0.17-1.11). LIMITATIONS, REASONS FOR CAUTION: This meta-analysis is based on abstracted data and most of the studies included are retrospective cohort studies. Not all studies had matching criteria between the study population and the controls, and these criteria often differed between the studies. Moreover, rate of recurrence is reported as a punctual event and it is not possible to establish when recurrences occurred and whether follow-up, which was shorter than 5 years in some of the included studies, is adequate to capture late recurrences. WIDER IMPLICATIONS OF THE FINDINGS: Our results demonstrate that performing COS at diagnosis or ART following treatment completion does not seem to be associated with detrimental prognostic effect in young women with breast cancer, including among patients with hormone receptor-positive disease and those receiving neoadjuvant chemotherapy. STUDY FUNDING/COMPETING INTEREST(S): Partially supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC; grant number MFAG 2020 ID 24698) and the Italian Ministry of Health-5 × 1000 funds 2017 (no grant number). M.L. acted as consultant for Roche, Pfizer, Novartis, Lilly, AstraZeneca, MSD, Exact Sciences, Gilead, Seagen and received speaker honoraria from Roche, Pfizer, Novartis, Lilly, Ipsen, Takeda, Libbs, Knight, Sandoz outside the submitted work. F.S. acted as consultant for Novartis, MSD, Sun Pharma, Philogen and Pierre Fabre and received speaker honoraria from Roche, Novartis, BMS, MSD, Merck, Sun Pharma, Sanofi and Pierre Fabre outside the submitted work. I.D. has acted as a consultant for Roche, has received research grants from Roche and Ferring, has received reagents for academic clinical trial from Roche diagnostics, speaker's fees from Novartis, and support for congresses from Theramex and Ferring outside the submitted work. L.D.M. reported honoraria from Roche, Novartis, Eli Lilly, MSD, Pfizer, Ipsen, Novartis and had an advisory role for Roche, Eli Lilly, Novartis, MSD, Genomic Health, Pierre Fabre, Daiichi Sankyo, Seagen, AstraZeneca, Eisai outside the submitted work. The other authors declare no conflict of interest. The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript and decision to submit the manuscript for publication. REGISTRATION NUMBER: N/A.
引用
- Arecco L, Blondeaux E, Bruzzone M, et al. Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis. Hum Reprod. 2022. PMID: 35220429. doi:10.1093/humrep/deac035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。